Safety and Effectiveness of Transhepatic Access for Percutaneous Renal Mass Cryoablation: A Multicenter Cohort.

To establish transhepatic percutaneous cryoablation of renal masses as a safe and effective approach. A retrospective review of records from 3 separate medical centers was performed identifying 23 patients (median age, 63 years [range 41-84 years]; 12 female [52.2%]) who underwent percutaneous transhepatic cryoablation for right-sided renal masses (median diameter, 2.4 cm [1.5-4.6 cm]) between 2008 and 2021. The median radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, and location relative to polar lines (RENAL) nephrometry score was 5 (4-10). Adverse events (AEs) were classified according to the Society of Interventional Radiology (SIR) and Clavien-Dindo (CD) classifications. Primary and secondary technical success of each procedure were recorded. Renal cell carcinoma (of any subtype) was found in 10 (71.5%) of the 14 masses that were biopsied. Tract cautery was used for transhepatic probes in 14 (63.6%) of 22 procedures. Three (13%) of 23 patients had postprocedural AEs. Two cases (8.6%) were hemorrhages related to transhepatic access (SIR moderate-2, CD 2; SIR severe-3, CD 1), and 1 case (4.4%) was related to bowel injury (SIR severe-3, CD 3a). There were no instances of pneumothorax. Tract cautery was used in the procedures that resulted in an AE. Primary technical success was achieved in 84.2% (16/19) of procedures, whereas secondary technical success was achieved in 2 additional patients. The secondary technical success rate was 94.7% (18/19). Four patients did not have imaging follow-up. The transhepatic approach to cryoablation of renal masses appears to have an acceptable safety profile and technical success rate. Larger studies, preferably comparative to nontranshepatic approach, are recommended.

Informations de copyright

Copyright © 2022 SIR. Published by Elsevier Inc. All rights reserved.